Simvastatin 10 mg Tablets Recalled for Manufacturing Practice Deviations
RemedyRepack Inc. voluntarily recalled Simvastatin 10 mg tablets nationwide due to manufacturing practice deviations. The recall affects specific lots distributed to consignees throughout the United States.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall without any reported illnesses or injuries. Per the rubric, a Class II recall without hospitalization reports or confirmed adverse events, where the hazard is theoretical, scores as 'High' (3).
Plain-English summary
RemedyRepack Inc., located in Indiana, Pennsylvania, initiated a voluntary recall of Simvastatin 10 mg tablets due to current Good Manufacturing Practice deviations. The company distributed affected lots to consignees nationwide within the United States.
The recalled product consists of two packaging formats: 30-count bottles (NDC 70518-0064-01, 1,262 units) and 90-count bottles (NDC 70518-0064-00, 95 units). Multiple lots with various expiration dates from April 2023 through February 2025 are included. The recall was initiated March 20, 2023, and terminated October 19, 2023.
Patients who have received affected tablets should contact their healthcare provider or pharmacist for guidance on their Simvastatin therapy.
The recalled product
- Product
- Simvastatin 10 mg tablets, packaged in a) 30-count bottles (NDC 70518-0064-01) and b) 90-count bottles (NDC 70518-0064-00), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (19)
- Lot #: a) J0675206-011223
- J0669260-121922
- Exp. Date 01/31/2024
- J0656820-103122
- J0647161-091722
- Exp. Date 09/30/2023 Exp. Date 11/30/2023
- J0621491-052722
- Exp. Date 06/30/2023
- J0638138-080822
- Exp. Date 08/31/2023
- J0610887-041122
- Exp. Date 04/30/2023. Lot # b) B1887315-100422
- Exp. Date 02/28/2024
- B1829906-083122
- B1769715-071622
- Exp. Date 09/30/2023
- B1906605-101422
- B1965118-111622
- Exp. Date 02/28/2025.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 14 recalled by RemedyRepack Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 14 products in this recall →Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · manufacturing deviation
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06